Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes

2 RCTs (n=312 and n=315) found, that in reduced or preserved ejection fraction heart failure, there were no significant differences between empagliflozin and placebo for the 6-minute walk test distance, dyspnoea scores and cardiomyopathy scores.

Source:

European Heart Journal